My Opinion on Vaccine Stocks
The full FDA approval of Pfizer-BioNTech COVID-19 vaccine for age 16 and above is likely to give a boost to investors’ confidence in $Pfizer(PFE.US$ and $BioNTech(BNTX.US$ as it can lead to more people taking the vaccine. Pfizer-BioNTech enjoys a first mover advantage as its MRNA vaccine was the first to be issued EUA by FDA. With booster shots being advocated and more companies requiring their employees to be vaccinated, it can only mean more revenue.
Moderna is close behind as the second vaccine to receive the EUA from FDA. It has just completed submission to FDA tor full approval of the vaccine for age 18 and older. The stock price of $Moderna(MRNA.US$ has rallied a lot recently due to it joining S&P 500 $SPDR S&P 500 ETF(SPY.US$ so it remains to be seen whether it can still make new highs.
Moderna is close behind as the second vaccine to receive the EUA from FDA. It has just completed submission to FDA tor full approval of the vaccine for age 18 and older. The stock price of $Moderna(MRNA.US$ has rallied a lot recently due to it joining S&P 500 $SPDR S&P 500 ETF(SPY.US$ so it remains to be seen whether it can still make new highs.
For the other vaccine stocks, the prospects may be less clear. As more countries try to develop their own local vaccines, the competition will become stiffer and the number of potential buyers may decrease.
The Oxford vaccine licensed by $AstraZeneca(AZN.US$ has been mired in a number of controversies and it has yet to receive EUA from the FDA. There is word the company is reviewing the long term sustainability of the COVID-19 vaccine business.
$Novavax(NVAX.US$ has received much interest in its non-MRNA vaccine but until it is rolled out, there may still be unknowns with regards to its performance and safety.
Last but not least, it is important to note that pharmaceutical business goes beyond the COVID-19 vaccine so the stock price can be affected by non-vaccine related developments.
Disclaimer: The above is not financial advice and should not be taken as a recommendation to invest. Please do your due diligence and consult your financial adviser before making any investment decision.
![]()
If you enjoy reading this article, you may also be interested in
![]()
“California Streaming” and Aapl’s Short Term Outlook https://www.moomoo.com/en-sg/community/feed/106924953829382?lang_code=2
![]()
Highest Returns To Date https://www.moomoo.com/en-sg/community/feed/106911175344134?lang_code=2
![]()
Great CEOs: Tim Cook and Steve Jobs https://www.moomoo.com/en-sg/community/feed/106837029355526?lang_code=2
The Oxford vaccine licensed by $AstraZeneca(AZN.US$ has been mired in a number of controversies and it has yet to receive EUA from the FDA. There is word the company is reviewing the long term sustainability of the COVID-19 vaccine business.
$Novavax(NVAX.US$ has received much interest in its non-MRNA vaccine but until it is rolled out, there may still be unknowns with regards to its performance and safety.
Last but not least, it is important to note that pharmaceutical business goes beyond the COVID-19 vaccine so the stock price can be affected by non-vaccine related developments.
Disclaimer: The above is not financial advice and should not be taken as a recommendation to invest. Please do your due diligence and consult your financial adviser before making any investment decision.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
gas 1126 : thanks for your sharing
gooup8 :
mesapsa : thx sharing
mesapsa :
搞经济 抄底 加仓 : Whenever good news arrived. Things goes south
Just another day
Pochong : Whats the use? The stock and premarket crashing down on Vaccine stock
有钱讲大话没钱少说话 : Agreed!
ROYTANKY : Buy on rumour sell on news
KayZeeee : I am going to buy and hold it
Kit Kat Crazy : if these are safe, their price will be better
View more comments...